Venatorx Pharmaceuticals is a technology company.
Venatorx Pharmaceuticals has raised $76.0M across 2 funding rounds.
Venatorx Pharmaceuticals has raised $76.0M in total across 2 funding rounds.
Venatorx Pharmaceuticals has raised $76.0M in total across 2 funding rounds.
Venatorx Pharmaceuticals's investors include AMR Action Fund, Boehringer Ingelheim Venture Fund, Vivo Capital, General Atlantic, Versant Ventures.
VenatoRx Pharmaceuticals is a private, clinical-stage biopharmaceutical company specializing in the discovery and development of novel anti-infectives to combat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections.[1][2][3] Its lead product, VNRX-5133, is an injectable beta-lactamase inhibitor (BLI) combined with cefepime, targeting carbapenem-resistant pathogens like CRE and CRPA, bioterror agents, and polymicrobial infections, with potential as a best-in-class broad-spectrum treatment.[1] The company serves patients with severe infections, healthcare providers, and global health organizations, addressing the critical problem of antibiotic resistance where existing therapies fail.[1][2][3] Backed by $54.9M in funding from investors like Versant Ventures, Abingworth, Foresite Capital, and grants from NIAID, Wellcome Trust, CARB-X, and DTRA, VenatoRx maintains a preclinical pipeline including oral BLIs, novel PBP inhibitors, and antivirals, with recent commercial deals like the Menarini Group agreement for cefepime-taniborbactam in 96 countries signaling growth momentum.[1][2]
Founded in 2010 in Malvern, Pennsylvania, by three antimicrobial R&D veterans, VenatoRx started as a virtual company with seed funding from a multi-million-dollar, three-year NIH grant to pursue novel molecules against drug-resistant infections.[2][3] The founders leveraged their pharma expertise to target emerging beta-lactamase resistance, evolving from preclinical focus to a clinical-stage operation with a 50-person team and five pipeline projects.[3] Early traction came from non-dilutive grants and private investments, enabling nimble adaptation to MDR threats; pivotal moments include advancing VNRX-5133 into combination development and securing partnerships amid intensifying global resistance.[1][3]
VenatoRx rides the global antimicrobial resistance (AMR) crisis, where MDR bacteria like CRE and CRPA cause millions of deaths annually, driven by overuse and innovation gaps in anti-infectives.[1][3] Timing is critical amid post-pandemic bioterror concerns and WHO priorities, with market forces like government incentives (e.g., CARB-X) and pull programs favoring novel agents over generics.[1][3] The company influences the ecosystem by sharing AMR surveillance data via Vivli, advancing preclinical platforms for new antibiotics, and forging commercialization pacts that expand access in underserved regions.[2][4] As a biotech leader, it counters Big Pharma's retreat from antibiotics, bolstering the pipeline against "superbugs" and viral threats.[3]
VenatoRx is poised for Phase 3 trials and regulatory approvals of cefepime/VNRX-5133, with Menarini commercialization accelerating revenue in 2026+ across 96 countries.[2] Pipeline expansion into oral therapies and antivirals will capitalize on rising AMR trends, bolstered by sustained grant funding and investor support amid escalating resistance waves.[1][3] Its influence may grow through more global partnerships and data platforms, potentially reshaping MDR treatment standards—positioning it as a key player in an ecosystem desperate for innovation, much like its origins tackling unmet resistance needs.[1][2]
Venatorx Pharmaceuticals has raised $76.0M across 2 funding rounds. Most recently, it raised $34.0M Series C in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $34.0M Series C | AMR Action Fund, Boehringer Ingelheim Venture Fund, Vivo Capital | |
| Jul 1, 2017 | $42.0M Series B | General Atlantic, Versant Ventures |